Nasdaq · Healthcare
Innoviva, Inc. (INVA)
As-reported financials and recent SEC filings for Innoviva, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$411.3M
Net income
$271.2M
Net margin
65.9%
Diluted EPS
$3.30
ROE
23.1%
P/E (TTM)
3.8×
Market cap
$1.74B
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $411.3M | $358.7M | $310.5M | $331.3M | $391.9M |
| Gross profit | — | — | — | — | — |
| Operating income | $163.7M | $166.9M | $113.9M | — | $375.1M |
| Net income | $271.2M | $23.4M | $179.7M | $220.3M | $368.8M |
| Diluted EPS | $3.30 | $0.36 | $2.20 | $2.37 | $2.87 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-20
View on EDGAR →32026-05-20
View on EDGAR →8-K2026-05-18
View on EDGAR →SCHEDULE 13D/A2026-05-13
View on EDGAR →10-Q2026-05-06
View on EDGAR →Go deeper on INVA
Search Innoviva, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.